Preferred Name |
ulipristal acetate |
|
Synonyms |
VA-2914 |
|
Definitions |
An orally bioavailable, acetate ester of ulipristal, a selective progesterone receptor modulator with anti-progesterone activity. Ulipristal binds to the progesterone receptor (PR), thereby inhibiting PR-mediated gene expression, and interfering with progesterone activity in the reproductive system. As a result, this agent may suppress the growth of uterine leiomyomatosis. Furthermore, by inhibiting or delaying ovulation and effecting endometrial tissue, ulipristal can be used as an emergency contraception. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C91056" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C91056" NCI Thesaurus) |
|
ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000729448 |
|
altLabel |
VA-2914 PGL-4001 CDB-2914 RTI-3021-012 Esmya |
|
cui |
C2723461 C4508920 C2745691 C0300207 C3154895 C2350670 |
|
DATE FIRST PUBLISHED |
2012-03-20 |
|
Date last modified |
2018-09-19 |
|
definition |
An orally bioavailable, acetate ester of ulipristal, a selective progesterone receptor modulator with anti-progesterone activity. Ulipristal binds to the progesterone receptor (PR), thereby inhibiting PR-mediated gene expression, and interfering with progesterone activity in the reproductive system. As a result, this agent may suppress the growth of uterine leiomyomatosis. Furthermore, by inhibiting or delaying ovulation and effecting endometrial tissue, ulipristal can be used as an emergency contraception. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C91056" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C91056" NCI Thesaurus) |
|
LT |
TRD |
|
NCI ID |
C91056 |
|
notation |
CDR0000729448 |
|
ORIG STY |
Drug/agent |
|
prefLabel |
ulipristal acetate |
|
tui |
T109 T121 |